MCE 的所有产品仅用作科学研究，我们不为任何个人用途提供产品和服务。

MRTX849

CAS No. : 2326521-71-3

MCE 站：MRTX849

产品活性：MRTX849 是一种有效，口服可用，突变选择性的 KRAS G12C 共价抑制剂，具有潜在抗肿瘤活性的。MRTX849 在半胱氨酸 12 残基处与 KRAS G12C 共价结合，将蛋白锁定在非活性的 GDP 结合构象中，并抑制 KRAS 依赖性信号转导。

研究领域：GPCR/G Protein

作用靶点：Ras

In Vitro: MRTX849 (0.1-10000 nM; 3-day/2D conditions; 12-day/3D conditions) potently inhibits cell growth in the vast majority of KRAS G12C-mutant cell lines with IC₅₀s ranging between 10 and 973 nM in the 2D format and between 0.2 and 1042 nM in the 3D format.
MRTX849 (0.24-1000 nM; 24 hours) inhibits KRAS-dependent signaling targets including ERK1/2 phosphorylation (Thr202/Tyr204 ERK1; pERK), S6 phosphorylation (RSK-dependent Ser235/236; pS6) and expression of the ERK-regulated DUSP6.

In Vivo: MRTX849 (1-100 mg/kg; i.g.; daily until day 16) demonstrates dose-dependent anti-tumor efficacy over a well-tolerated dose range, and the maximally efficacious dose of MRTX849 is between 30-100 mg/kg/day.

相关产品：Covalent Screening Library Plus  |  Drug Repurposing Compound Library  |  Orally Active Compound Library  |  GPCR/G Protein Compound Library  |  Covalent Screening Library  |  Clinical Compound Library  |  Clinical Compound Library Plus  |  Glutamine Metabolism Compound Library  |  Ferroptosis Compound Library  |  Anti-Cancer Compound Library  |  Drug Repurposing Compound Library Plus  |  Bioactive Compound Library Plus  |  AMG-510  |  ARS-1620  |  NSC 23766 trihydrochloride  |  BI-2852  |  MRTX-1257  |  Pan-RAS-IN-1  |  Rhosin hydrochloride  |  ARS-853  |  BAY-293  |  ML141  |  Salirasib  |  BI-3406  |  EHT 1864  |  CASIN  |  EHop-016  |  1A-116  |  ZCL278  |  GGTI298  |  CID-1067700  |  CCG-1423  |  Y16  |  MBQ-167  |  CCG-203971  |  K-Ras(G12C) inhibitor 12  |  PROTAC K-Ras Degrader-1  |  Kobe0065  |  ML-098  |  CCG-222740

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。